Therapeutic effects of ketone formula in patients with intractable epilepsy

DOI
  • Takahashi Yukitoshi
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka Department of Pediatrics, Gifu University School of Medicine, Gifu School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka
  • Imai Katsumi
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Yamaguchi Tokito
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Oboshi Taikan
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Ikeda Hiroko
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Yoshitomi Shinsaku
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Kimizu Tomokazu
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Koike Takayoshi
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Horino Asako
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
  • Oomatsu Hiroo
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka

Bibliographic Information

Other Title
  • ケトンフォーミュラの難治てんかん症例における治療効果

Search this article

Description

<p>  Objective: The therapeutic and medical social effects of ketogenic diet (KD) in children with epilepsy were examined. Methods: A retrospective study was conducted in 53 patients (mean start age 8.2 months, range 0.1-50 months) with intractable epielpsy, who were treated by KD with ketone formula. Results: Seizure-free rate was 11.3% (6/53) in all patients, 100% (3/3) in glucose trasporter 1 deficiency syndrome (GT-1D) patients, 16.7% (1/6) in syptomatic generalized epilepsy patients, and 13.3% (2/15) in symptomatic localization-related epilepsy patients. The proportion of patients who continued KD was 34% (18/53) in all patients, 100% (3/3) in patients with GT-1D, 50% (3/6) in patients with symptomatic generalized epilepsy, and 30% (3/10) in patients with Dravet syndrome. The duration (mean±SD) of KD was 663.0±717.3 days. After the initiation of KD, hospital stay, visit of emergency ambulance, and use of ambulance car were reduced, and days of attending school, kindergarten, etc. were increased in some patients. Motor developmental score increased in 8 patients, and cognitive developmental score in 7 patients. Conclusions: Use of KD in children was effective for inhibition of epileptic seizures in some patients with intractable epilepsy</p>

Journal

  • NO TO HATTATSU

    NO TO HATTATSU 50 (1), 44-49, 2018

    The Japanese Society of Child Neurology

Keywords

Details 詳細情報について

Report a problem

Back to top